Type Public NASDAQ: NBIX Founded 1992 Website www.neurocrine.com Founder Kevin C. Gorman | Industry Biotechnology Number of employees 95 (2015) CEO Kevin C. Gorman | |
 | ||
Key people Bill Rastetter, Chairman
Kevin C. Gorman, CEO/President Stock price NBIX (NASDAQ) US$ 41.98 +0.48 (+1.16%)24 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters San Diego, California, United States Subsidiaries Neurocrine International LLC, Neurocrine HQ, Inc | ||
Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company took its name from the original focus on therapies for neurological and endocrine diseases and disorders.
Medications
On May 16, 2006 when the Food and Drug Administration (FDA) denied approval for the 15-milligram dose of Indiplon, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner Pfizer. As a result of the denial, the stock price fell significantly and the company laid off 300 employees in 2006. In 2007 Neurocrine showed a fourth quarter loss of $128 million, including a $94 million write-off, with a further layoff of half the remaining workforce.
In 2010 the company announced that its drug to treat endometriosis had achieved its main and secondary goals in a study. The drug, called elagolix, reportedly showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation as well as painful intercourse. As of 2016 the drug, being developed in cooperation with AbbVie, is in phase III clinical trials.
As of 2016 the company has a drug in development, called Ingrezza, for treatment of tardive dyskinesia. There are currently no approved treatments for this condition. The United States Food and Drug Administration has agreed to review the drug's application under fast-track priority status.